Emerging Stock Report Initiates Independent Research Coverage on Fresenius Kabi Pharmaceuticals Holding, Inc.
25 März 2010 - 2:15PM
Emerging Stock Report, a leading provider of sector specific
independent investment research, today initiated coverage on
Fresenius Kabi Pharmaceuticals Holding, Inc. (Nasdaq:APCVZ).
Emerging Stock Report is currently offering a complimentary trial
subscription to the investment community.
To view the Report in its entirety visit:
http://www.emergingstockreport.com
To get our alerts AHEAD of the market follow us on Twitter:
http://twitter.com/EmergingStockRe
About ESR:
Emerging Stock Report is a leading provider of independent
investment research for North American companies. Our services
include research analysis on emerging growth companies, sector
specific research, real-time news and financial data, market
commentary and the ESR newsletter. Emerging Stock Report's staff of
investment professionals are dedicated to providing the tools and
resources necessary to help make important investment decisions. To
view our research reports on a complimentary trial basis and take
advantage of our other services, visit
http://www.emergingstockreport.com and click on the complimentary
trial subscription button on our home page, or go directly to our
registration page at
http://emergingstockreport.com/register.php
About Fresenius Kabi Pharmaceuticals Holding, Inc.
(Nasdaq:APCVZ)
Fresenius Kabi Pharmaceuticals Holding, Inc. (Nasdaq:APCVZ) is
an integrated pharmaceutical company that develops, manufactures
and markets injectable pharmaceutical products. The Company
primarily focuses on the injectable oncology, anti-infective,
anesthetic/analgesic and critical care markets.
ESR Disclosure:
Emerging Stock Report is not a registered investment advisor and
nothing contained in any materials should be construed as a
recommendation to buy or sell any securities. Emerging Stock Report
has not been compensated by any of the above mentioned companies.
Please read our report and visit our Web site,
http://www.EmergingStockReport.com, for complete risks and
disclosures.
CONTACT: Emerging Stock Report
Joshua Anderson
1 (310) 341 7000
info@emergingstockreport.com
Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (NASDAQ:APCVZ)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (NASDAQ:APCVZ)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
Echtzeit-Nachrichten über Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere News-Artikel